KORU Medical Systems (NASDAQ:KRMD) CTO Eric Schiller Purchases 5,000 Shares

KORU Medical Systems, Inc. (NASDAQ:KRMD) CTO Eric Schiller purchased 5,000 shares of the business’s stock in a transaction dated Monday, May 18th. The shares were purchased at an average cost of $3.91 per share, with a total value of $19,550.00. Following the purchase, the chief technology officer directly owned 5,000 shares in the company, valued at approximately $19,550. The trade was a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

KORU Medical Systems Trading Up 1.0%

Shares of NASDAQ:KRMD traded up $0.04 during midday trading on Wednesday, hitting $4.00. 111,917 shares of the stock were exchanged, compared to its average volume of 172,817. KORU Medical Systems, Inc. has a twelve month low of $2.63 and a twelve month high of $6.61. The company has a 50 day moving average price of $4.21 and a 200-day moving average price of $4.84. The stock has a market cap of $183.73 million, a P/E ratio of -80.00 and a beta of 0.43.

KORU Medical Systems (NASDAQ:KRMD) last issued its quarterly earnings data on Wednesday, May 6th. The company reported ($0.02) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.02). KORU Medical Systems had a negative return on equity of 13.61% and a negative net margin of 5.27%.The business had revenue of $11.76 million for the quarter, compared to the consensus estimate of $11.28 million. On average, equities research analysts expect that KORU Medical Systems, Inc. will post -0.04 earnings per share for the current year.

Analyst Upgrades and Downgrades

KRMD has been the topic of several recent research reports. Weiss Ratings restated a “sell (d-)” rating on shares of KORU Medical Systems in a research report on Tuesday, April 21st. B. Riley Financial upped their price objective on KORU Medical Systems from $7.00 to $8.00 and gave the company a “buy” rating in a research report on Friday, March 13th. Canaccord Genuity Group restated a “buy” rating and issued a $6.00 price objective on shares of KORU Medical Systems in a research report on Friday, March 13th. Finally, Wall Street Zen downgraded KORU Medical Systems from a “buy” rating to a “hold” rating in a research report on Saturday, May 9th. Four investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $7.25.

Hedge Funds Weigh In On KORU Medical Systems

Institutional investors have recently added to or reduced their stakes in the business. Bank of America Corp DE increased its stake in KORU Medical Systems by 36.0% during the first quarter. Bank of America Corp DE now owns 37,971 shares of the company’s stock worth $164,000 after acquiring an additional 10,045 shares during the last quarter. Royal Bank of Canada increased its stake in KORU Medical Systems by 77.3% during the first quarter. Royal Bank of Canada now owns 235,804 shares of the company’s stock worth $1,019,000 after acquiring an additional 102,800 shares during the last quarter. Vivaldi Capital Management LP increased its stake in KORU Medical Systems by 51.6% during the first quarter. Vivaldi Capital Management LP now owns 29,885 shares of the company’s stock worth $129,000 after acquiring an additional 10,172 shares during the last quarter. Renaissance Technologies LLC acquired a new stake in KORU Medical Systems during the first quarter worth about $198,000. Finally, Arrowstreet Capital Limited Partnership acquired a new stake in KORU Medical Systems during the first quarter worth about $79,000. 58.60% of the stock is currently owned by institutional investors and hedge funds.

KORU Medical Systems Company Profile

KORU Medical Systems, Inc develops and manufactures medical devices and supplies in the United States and internationally. It offers the freedom infusion systems to deliver life-saving therapies to patients with chronic illnesses, such as primary immunodeficiency diseases, chronic inflammatory demyelinating polyneuropathy, and paroxysmal nocturnal hemoglobinuria. Its products include the FREEDOM60 syringe infusion system, the FreedomEdge syringe driver, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing products.